Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Hikma Pharmaceuticals ( (GB:HIK) ).
Hikma Pharmaceuticals has continued executing its $250 million share repurchase programme, buying back 751,289 ordinary shares between 16 and 20 March 2026 via Citigroup Global Markets, at volume‑weighted average prices in the mid‑1,200 pence range. The company plans to cancel these shares, and since the buyback’s launch has repurchased 3,077,665 shares for £38.4 million, reducing its free float to 218,808,788 voting shares and modestly enhancing earnings per share and capital returns for investors.
Following the latest transactions, Hikma holds 12,833,233 shares in treasury and reports a total of 218,808,788 voting rights outstanding, refining its capital structure while maintaining liquidity in its London and Cboe Europe listings. The ongoing buyback underlines management’s confidence in the business and signals a disciplined approach to balance sheet optimisation, which may support shareholder value and price performance over time.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £2300.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational generic drug manufacturer listed in London and on Nasdaq Dubai, supplying injectable and oral medicines across the U.S., MENA and European markets. The company focuses on branded and non‑branded generics, with a portfolio geared toward hospitals and healthcare systems seeking cost‑effective treatments.
Average Trading Volume: 1,258,227
Technical Sentiment Signal: Sell
Current Market Cap: £2.73B
See more insights into HIK stock on TipRanks’ Stock Analysis page.